

James D Marks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7450090/publications.pdf>

Version: 2024-02-01

37
papers

1,031
citations

471509

17
h-index

434195

31
g-index

38
all docs

38
docs citations

38
times ranked

1135
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. <i>Nature Biotechnology</i> , 2007, 25, 107-116.	17.5	165
2	A Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic \pm -Exosite Binding Region. <i>Journal of Molecular Biology</i> , 2010, 397, 1106-1118.	4.2	78
3	Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. <i>Human Antibodies</i> , 1996, 7, 97-105.	1.5	69
4	Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. <i>Movement Disorders</i> , 2004, 19, S101-S108.	3.9	68
5	Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. <i>Cancer Gene Therapy</i> , 2001, 8, 555-565.	4.6	65
6	Extraction of BoNT/A, /B, /E, and /F with a Single, High Affinity Monoclonal Antibody for Detection of Botulinum Neurotoxin by Endopep-MS. <i>PLoS ONE</i> , 2010, 5, e12237.	2.5	53
7	Selection of Human Antibodies from Phage Display Libraries. , 2004, 248, 161-176.		41
8	Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. <i>Nature Biomedical Engineering</i> , 2019, 3, 264-280.	22.5	40
9	Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. <i>Journal of Infectious Diseases</i> , 2016, 213, 1606-1614.	4.0	36
10	Medical aspects of biologic toxins. <i>Anesthesiology Clinics</i> , 2004, 22, 509-532.	1.4	33
11	A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. <i>Toxins</i> , 2018, 10, 105.	3.4	30
12	Anti-MET ImmunoPET for Nonâ€“Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2607-2617.	4.1	29
13	Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ^{64}Cu -DOTA conjugation. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 317-324.	2.1	27
14	A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. <i>PLoS ONE</i> , 2017, 12, e0174187.	2.5	27
15	Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. <i>MAbs</i> , 2017, 9, 58-67.	5.2	23
16	A fully human scFv phage display library for rapid antibody fragment reformatting. <i>Protein Engineering, Design and Selection</i> , 2015, 28, 307-316.	2.1	22
17	Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution. <i>Anesthesiology and Pain Medicine</i> , 2015, 5, e26300.	1.3	20
18	Antibody Affinity Maturation by Chain Shuffling. , 2004, 248, 327-344.		18

#	ARTICLE	IF	CITATIONS
19	Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins, 2015, 7, 3405-3423.	3.4	18
20	Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins, 2019, 11, 208.	3.4	18
21	The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA. Toxins, 2020, 12, 9.	3.4	16
22	High Throughput Identification of Monoclonal Antibodies to Membrane Bound and Secreted Proteins Using Yeast and Phage Display. PLoS ONE, 2014, 9, e111339.	2.5	15
23	Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination against Botulinum C and D Neurotoxins. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
24	Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS ONE, 2015, 10, e0135306.	2.5	15
25	PCR Cloning of Human Immunoglobulin Genes. , 2004, 248, 117-134.		14
26	Selection of Internalizing Antibodies for Drug Delivery. , 2004, 248, 201-208.		12
27	Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies. PLoS ONE, 2014, 9, e112376.	2.5	11
28	Antibody engineering to improve manufacturability. Protein Expression and Purification, 2018, 149, 75-83.	1.3	8
29	A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Toxins, 2018, 10, 84.	3.4	8
30	Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Toxins, 2019, 11, 345.	3.4	8
31	Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics, 2020, 12, 996.	4.5	6
32	A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model. Toxins, 2021, 13, 31.	3.4	6
33	A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D. Toxins, 2021, 13, 641.	3.4	6
34	Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model. Toxins, 2021, 13, 671.	3.4	5
35	Discovery of internalizing antibodies to basal breast cancer cells. Protein Engineering, Design and Selection, 2018, 31, 17-28.	2.1	4
36	Infectious Disease and Bioterrorism. Anesthesiology Clinics, 2004, 22, xiii-xv.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Selection of improved peptide ligases by yeast surface display. FASEB Journal, 2012, 26, 549.3.	0.5	0